絞り込み

17799

広告

新型コロナ 寮の部員ら88人感染 松江の高校サッカー部 (毎日新聞)

松江市で新型コロナウイルスへの感染が明らかになった91人について、市と島根県は9日夜、88人が立正大淞南(しょうなん)高校(北村直樹校長、生徒数309人)のサッ...

  1. 新型コロナ 両陛下、国民との交流模索 専...
  2. 生きる:小児がん征圧キャンペーン オンラ...
  3. 新型コロナ 両陛下、国民との交流模索 専...
  4. 異変のシグナル:「カネミ油症」救済になお...

ニュース一覧

スターを付ける スターを付ける     (4view , 1users)

Full Text Sources

Medical

A fundamental question in advancing Parkinson disease (PD) research is whether it represents one disorder or many. Does each genetic PD inform a common pathobiology or represent a unique entity? Do the similarities between genetic and idiopathic forms of PD outweigh the differences? If aggregates of α-synuclein in Lewy bodies and Lewy neurites are present in most (α-synucleinopathies), are they also etiopathogenically significant in each (α-synuclein pathogenesis)? Does it matter that postmortem studies in PD have demonstrated that mixed protein-aggregate pathology is the rule and pure α-synucleinopathy the exception? Should we continue to pursue convergent biomarkers that are representative of the diverse whole of PD or subtype-specific, divergent biomarkers, present in some but absent in most? Have clinical trials that failed to demonstrate efficacy of putative disease-modifying interventions been true failures (shortcomings of the hypotheses, which should be rejected) or false failures (shortcomings of the trials; hypotheses should be preserved)? Each of these questions reflects a nosologic struggle between the lumper's clinicopathologic model that embraces heterogeneity of one disease and the splitter's focus on a pathobiology-specific set of diseases. Most important, even if PD is not a single disorder, can advances in biomarkers and disease modification be revised to concentrate on pathologic commonalities in large, clinically defined populations? Or should our efforts be reconstructed to focus on smaller subgroups of patients, distinguished by well-defined molecular characteristics, regardless of their phenotypic classification? Will our clinical trial constructs be revised to target larger and earlier, possibly even prodromal, cohorts? Or should our trials efforts be reconstructed to target smaller but molecularly defined presymptomatic or postsymptomatic cohorts? At the Krembil Knowledge Gaps in Parkinson's Disease Symposium, the tentative answers to these questions were discussed, informed by the failures and successes of the fields of breast cancer and cystic fibrosis.
PMID: 32102975 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード